Related Experiment Video
Updated: Aug 19, 2026
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture
P E Lazzerini1, P L Capecchi, F Nerucci
1Department of Clinical Medicine and Immunological Sciences, Division of Clinical Immunology, University of Siena, Policlinico "Le Scotte", 53100 Siena, Italy.
Objectives:
Matrix metalloproteinases (MMPs) produced by chondrocytes play a role in the development of cartilage degradation in joint diseases. Moreover, inhibition of MMP secretion by macrophages accumulating in arteriosclerotic plaques would account for the plaque stabilising activity of statins in cardiovascular patients. Recently, simvastatin has been shown to inhibit both developing and established collagen induced arthritis in a murine model. We thus decided to investigate the effect of simvastatin on the production of MMP-3 from cultured interleukin (IL)1 stimulated human chondrocytes.
Methods:
Cells from human cartilage, obtained from eight subjects with osteoarthritis undergoing surgery for total hip prostheses, were cultured in the presence of different concentrations of simvastatin (5, 10, and 50 micromol/l) with and without IL1beta (5 ng/ml). MMP-3 level was measured in the culture medium after 48 h of incubation.
Results:
IL1beta stimulation of chondrocytes increased MMP-3 concentration in the cultures (from 0.69 (0.09) to 1.94 (0.12) ng/microg protein). Incubation with simvastatin was associated with a dose dependent reduction in MMP-3 increase, both in the presence (-15%, -17%, and -26% with 5, 10, and 50 micromol/l, respectively) and in the absence (-32% with 50 micromol/l) of IL1beta. The inhibiting effect of simvastatin was completely reversed by the addition of mevalonate (100 micromol/l) or farnesol (10 micromol/l).
Conclusions:
Our data show that simvastatin, by blocking HMGCoA-reductase and interfering in the prenylation processes, is able to inhibit MMP-3 production from cultured human chondrocytes that have been either unstimulated or stimulated with IL1beta, thus suggesting a possible additional mechanism for statins in counteracting chronic joint disease related cartilage damage.
Insights
Simvastatin reduces matrix metalloproteinase-3 (MMP-3) production in human chondrocytes, offering potential for treating joint diseases. This cholesterol-lowering drug may help counteract cartilage damage by inhibiting MMP-3 secretion.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Matrix metalloproteinases (MMPs) produced by chondrocytes contribute to cartilage degradation in joint diseases.
- Simvastatin, a statin drug, has demonstrated anti-arthritic effects in murine models.
- Understanding simvastatin's impact on MMP production is crucial for its therapeutic potential in cardiovascular and joint diseases.
Purpose of the Study:
- To investigate the effect of simvastatin on the production of MMP-3 in cultured human chondrocytes.
- To determine if simvastatin inhibits MMP-3 secretion stimulated by interleukin-1 beta (IL-1β).
Main Methods:
- Human chondrocytes from osteoarthritis patients were cultured with varying concentrations of simvastatin.
- Cells were stimulated with IL-1β, and MMP-3 levels in the culture medium were measured after 48 hours.
- The effect of mevalonate and farnesol on simvastatin's inhibitory action was assessed.
Main Results:
- IL-1β stimulation significantly increased MMP-3 concentration in chondrocyte cultures.
- Simvastatin exhibited a dose-dependent reduction in MMP-3 levels, both with and without IL-1β stimulation.
- The inhibitory effect of simvastatin was reversed by mevalonate and farnesol, indicating interference with prenylation pathways.
Conclusions:
- Simvastatin inhibits MMP-3 production in cultured human chondrocytes.
- This inhibition occurs through blocking HMG-CoA reductase and interfering with prenylation processes.
- These findings suggest a potential mechanism for statins in counteracting cartilage damage associated with chronic joint diseases.
